G L WAMPLER
Overview
Explore the profile of G L WAMPLER including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Auerbach M, WAMPLER G, Lokich J, Fryer D, Fryer J, Ahlgren J
Ann Oncol
. 1997 May;
8(5):439-44.
PMID: 9233522
Background: Advanced pancreatic cancer is a rapidly fatal disease whose course has been little influenced by chemotherapy. Earlier studies have shown some modest promise for the combination of protracted infusional...
2.
Hainsworth J, Levitan N, WAMPLER G, Belani C, Seyedsadr M, Randolph J, et al.
J Clin Oncol
. 1995 Jun;
13(6):1436-42.
PMID: 7751890
Purpose: This randomized phase II study evaluated the efficacy and toxicity of etoposide phosphate when used in combination with cisplatin in the treatment of small-cell lung cancer. Patients And Methods:...
3.
Ahlgren J, Ellison N, Gottlieb R, Laluna F, Lokich J, Sinclair P, et al.
J Clin Oncol
. 1993 Oct;
11(10):1957-68.
PMID: 7691999
Purpose: To evaluate the efficacy of three hormonal manipulations in the palliation of chemoresistant ovarian cancer, and to analyze the results in the light of other clinical trials. Patients And...
4.
Rosenthal C, WAMPLER G, Brereton H, Ahlgren J, Lokich J, Fryer J, et al.
Am J Clin Oncol
. 1992 Feb;
15(1):12-7.
PMID: 1312767
A combination of oral etoposide, infusional cisplatin (24-hr) and infusional 5-fluorouracil (5-day) was used to treat 87 patients with non-small-cell lung cancer in a Phase II trial. Twenty-six patients were...
5.
WAMPLER G, CARTER Jr W, Campbell E, Keefe P
Cancer Chemother Pharmacol
. 1992 Jan;
31(2):111-7.
PMID: 1333367
In in vitro testing, no pharmacologic synergism has been found for the combination of cisplatin and etoposide in P388 leukemia in contrast to the demonstration of therapeutic synergism in the...
6.
WAMPLER G, Fryer J
Cancer Chemother Pharmacol
. 1992 Jan;
30(3):199-206.
PMID: 1321006
Programs are presented for the calculation of received dose intensity in combination chemotherapy regimens. These provide methods for determining the final dose intensity, the mean cumulative dose intensity together with...
7.
WAMPLER G, Ahlgren J, Schulof R
Cancer Invest
. 1992 Jan;
10(2):97-102.
PMID: 1312886
An intensive weekly chemotherapeutic treatment for extensive disease small-cell lung cancer was piloted in 14 patients. The regimen consisted of 6 drugs. Two drugs were given each week for a...
8.
Heim W, WAMPLER G, Lokich J, Brereton H, Scialla S, Laluna F, et al.
J Clin Oncol
. 1991 Dec;
9(12):2162-6.
PMID: 1660065
A combination of cisplatin administered as a 24-hour infusion and fluorouracil administered as a 5-day infusion was used to treat 97 patients with non-small-cell lung (NSCLC) cancer in a phase...
9.
WAMPLER G, Ahlgren J, Lokich J, Gullo J, Phillips J
Am J Clin Oncol
. 1991 Oct;
14(5):442-5.
PMID: 1659178
The combination of dichloromethotrexate, cisplatin, and infusional 5-fluorouracil was evaluated as treatment for non-small-cell lung cancer in a phase II trial using 43 evaluable patients. Grade III or IV toxicity...
10.
WAMPLER G, HEIM W, Ellison N, Ahlgren J, Fryer J
J Clin Oncol
. 1991 Aug;
9(8):1438-45.
PMID: 1649265
An alternating regimen for the treatment of extensive-disease small-cell lung cancer (SCLC) was compared with standard treatment with cyclophosphamide, doxorubicin, and vincristine (CAV) in 170 patients. Overall severity of toxicity...